SEC Form 4 · accession 0001994071-26-000004
Immunome Inc. · IMNM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Max Rosett
Officer — Chief Financial Officer
Period of report
Jun 15, 2026
Accepted (ET)
Jun 17, 2026 · 5:26 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001472012
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 15, 2026 | M | 60,000 | $1.05 | A | 114,037 | D | |
| Common StockF2 | Jun 15, 2026 | S | 60,000 | $18.23 | D | 54,037 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $1.05 | Jun 15, 2026 | M | 60,000 | D | — | Mar 22, 2033 | Common Stock | 60,000 | 0 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025.
- F2The weighted average purchase price for the transaction report was $18.23, and the range of prices were between $17.95 and $18.66, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
- F3The option is fully vested.